Authors

Latest:

Advances in Metastatic Melanoma Bring Price Competition, Redefinition of Value, and Likely Increased Payer Utilization Management

Traditionally, payers have been increasingly more proactive in their management of drug expenditures in cancers with the highest prevalence and with the more costly therapeutics.

Gottfried E. Konecny, MD

Latest:

Optimizing Therapy for MMR-Proficient Endometrial Cancer

Panelists discuss how the DUO trial demonstrates the benefit of durvalumab in adjuvant endometrial cancer treatment and suggests potential value of adding olaparib in specific subgroups like mismatch repair–proficient patients, though emphasizing the need for confirmatory studies before routine clinical implementation.

Gottfried E. Konecny, MD, University of California, Los Angeles

Grace Cherry, NP

Latest:

Recent Advances in Melanoma

Grace Cherry, RN, MSN, NP, discusses recent advances in melanoma.

Graham Dixon, PhD

Latest:

Doxorubicin-Loaded Nanoparticle Formulation in Patients With HCC

Graham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma cell lines.

Graham Jackson, MD, PhD

Latest:

Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

Graham Mann

Latest:

Graham Mann on Genetic Mutations in Different Types of Melanoma

Graham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.

Graham W. Warren, MD, PhD

Latest:

Helping Cancer Patients Quit Smoking Should Be a Standard of Care

Most oncologists do not regularly provide evidence-based tobacco cessation support for patients with cancer who smoke. However, addressing tobacco use is not as difficult as some might think.

Grant McArthur, PhD

Latest:

Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced Melanoma

Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.

Grant W. Carlson, MD

Latest:

Dr. Carlson on Treating Breast Cancer Patients Under 40

Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, discusses treating younger patients with breast cancer.

Greg Kennelty

Latest:

Individualized Treatment Needed for Patients With NRAS-Mutated mCRC

Activating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.

Greg Riedlinger, MD, PhD, Rutgers University

Gregory A. Daniels, MD, PhD

Latest:

Dr. Daniels on Immunotherapy in Head and Neck Cancer

Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses the role of immunotherapy for patients with head and neck cancer.

Gregory A. Grabowski, MD

Latest:

Dr. Grabowski Explains the Effects of Enzyme Therapy

Dr. Gregory A. Grabowski from Cincinnati Children's Hospital Medical Center Explains the Effects of Enzyme Therapy

Gregory A. Otterson, MD

Latest:

Dr. Otterson on the Utility of Immunotherapy in NSCLC

Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.

Gregory E. Idos, MD

Latest:

Dr. Idos on Remaining Questions With Multiplex Panel Testing

Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the remaining questions with multiplex panel testing as well as the cost effectiveness of it.

Gregory J. Riely, MD, Memorial Sloan Kettering

Gregory J. Riely, MD PhD, Memorial Sloan Kettering Cancer Center

Gregory J. Riely, MD, PhD, Weill Cornell Medical College

Gregory L. Beatty, MD, PhD

Latest:

Dr. Beatty on the Potential for Immunotherapy in GI Malignancies

Gregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.